The effect of biologic disease modifying anti-rheumatic drugs on the neutrophil–lymphocyte ratio in psoriatic arthritis patients
Clinical Rheumatology · 2026-07 · 45 (7) · 4277-4285
DOI: 10.1007/s10067-026-08233-5 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Rheumatology, online erschienen am 19.06.2026. Verfasst von Martin Lauran und 6 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Department, Bedfordshire Hospitals NHS Foundation Trust, Dunstable University Hospital, Lewsey Rd, Luton, LU4 0DZ, UK. martinlauran123@h…. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Neutrophils, Lymphocytes, Antirheumatic Agents. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: Cardiovascular mortality is up to 43% greater in patients with Psoriatic Arthritis (PsA) when compared to the general population. Whilst composite cardiovascular disease risk prognosticators exist, an emerging inexpensive biomarker known as the neutrophil-lymphocyte ratio (NLR) has been demonstrated to be a risk-associated biomarker of cardiovascular disease (CVD) in the general population. This study therefore aimed to assess the effect of biologic disease modifying antirheumatic drug (bDMARDs) on the NLR in a cohort of adult patients diagnosed with PsA. METHODS: A retrospective single-centre observational study was conducted using an electronic health record database including 183 adult patients diagnosed with PsA between 1983 and 2024. The NLR of patients was calculated pre- and post-initiation of bDMARDs and statistical significance was analysed using several different statistical analysis tools. RESULTS: The overall number of patients in the higher NLR risk stratification group (NLR > 2) was significantly reduced from 104 to 64 post-biologic initiation. Additionally, there was a statistically significant reduction of 24.0% in the average NLR of the entire patient cohort from 2.58 to 1.96 pre- and post-biologic initiation respectively. CONCLUSION: Our study demonstrates that over a third of patients had a significant NLR reduction post-biologic initiation. The mean NLR of the entire patient cohort demonstrated a shift to a lower CVD risk-associated stratified NLR group (NLR < 2), post-biologic treatment. BDMARD treatment in PsA patients therefore demonstrates a significant reduction in the NLR metric, with a varying degree of theoretical impact on the CVD risk reduction among different biologic drugs and classes. Key Points • bDMARDs reduce the Neutrophil-Lymphocyte Ratio in Psoriatic Arthritis patients. • Both TNF inhibitor and IL-17 inhibitors bDMARDs were associated with significant reductions in the Neutrophil-Lymphocyte Ratio in Psoriatic Arthritis patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rheumatology Department, Bedfordshire Hospitals NHS Foundation Trust, Dunstable University Hospital, Lewsey Rd, Luton, LU4 0DZ, UK. martinlauran123@hotmail.com.
- Rheumatology Department, Bedfordshire Hospitals NHS Foundation Trust, Dunstable University Hospital, Lewsey Rd, Luton, LU4 0DZ, UK.
Zitieren
APA
Lauran, M., Kyeremateng, C., Haque, A., Rizal, S., Ahmed, H., Pandey, S., & Nisar, M. K. (2026). The effect of biologic disease modifying anti-rheumatic drugs on the neutrophil–lymphocyte ratio in psoriatic arthritis patients. Clinical Rheumatology, 45(7), 4277-4285. https://doi.org/10.1007/s10067-026-08233-5
Vancouver
Lauran M, Kyeremateng C, Haque A, Rizal S, Ahmed H, Pandey S, et al. The effect of biologic disease modifying anti-rheumatic drugs on the neutrophil–lymphocyte ratio in psoriatic arthritis patients. Clinical Rheumatology. 2026;45(7):4277-4285. doi:10.1007/s10067-026-08233-5
BibTeX
@article{Lauran2026,
author = {Lauran, Martin and Kyeremateng, Chelsea and Haque, Afrida and Rizal, Sara and Ahmed, Humairaa and Pandey, Samyak and Nisar, Muhammad K},
title = {The effect of biologic disease modifying anti-rheumatic drugs on the neutrophil–lymphocyte ratio in psoriatic arthritis patients},
journal = {Clinical Rheumatology},
year = {2026},
volume = {45},
number = {7},
pages = {4277--4285},
doi = {10.1007/s10067-026-08233-5}
}
EUVIMED